Review Article

Gut Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications

Lili Zhang,1 Jinjin Chu,1 Wenhao Hao,2 Jiaojiao Zhang,1 Haibo Li,1 Chunjuang Yang,3 Jinghan Yang,3 Xiaohua Chen,4 and Honggang Wang5

1Central Laboratory, Weifang People’s Hospital, Weifang 261000, China
2Department of Scientific Research Management, Weifang People’s Hospital, Weifang 261000, China
3Central Laboratory of the First Affiliated Hospital, Weifang Medical University, Weifang 261000, China
4Department of Nuclear Medicine, Weifang People’s Hospital, Weifang 261000, China
5Clinical Laboratory, Weifang People’s Hospital, Weifang 261000, China

Correspondence should be addressed to Xiaohua Chen; 2760370581@qq.com and Honggang Wang; wf661188@163.com

Received 14 April 2021; Accepted 26 July 2021; Published 17 August 2021

Academic Editor: Bingjie Gu

Copyright © 2021 Lili Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gut microbiota has attracted widespread attention due to its crucial role in disease pathophysiology, including type 2 diabetes mellitus (T2DM). Metabolites and bacterial components of gut microbiota affect the initiation and progression of T2DM by regulating inflammation, immunity, and metabolism. Short-chain fatty acids, secondary bile acid, imidazole propionate, branched-chain amino acids, and lipopolysaccharide are the main molecules related to T2DM. Many studies have investigated the role of gut microbiota in T2DM, particularly those butyrate-producing bacteria. Increasing evidence has demonstrated that fecal microbiota transplantation and probiotic capsules are useful strategies in preventing diabetes. In this review, we aim to elucidate the complex association between gut microbiota and T2DM inflammation, metabolism, and immune disorders, the underlying mechanisms, and translational applications of gut microbiota. This review will provide novel insight into developing individualized therapy for T2DM patients based on gut microbiota immunometabolism.

1. Introduction

Diabetes mellitus (DM) is a group of chronic metabolic diseases characterized by hyperglycemia. There are two most common forms, namely, type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T2DM accounts for about 90% of all diabetes cases, resulting from insulin resistance combined with impaired insulin secretion. DM can cause a variety of acute and chronic complications, such as blindness, amputation, heart disease, kidney failure, and premature death. According to the latest version of the diabetes map released by the International Diabetes Federation (IDF) in 2019, about 463 million adults worldwide suffer from diabetes, with an average growth rate of 51%. The number of diabetic patients will reach 700 million by 2045 with increasing economic burden for diabetes worldwide [1]. The pathogenesis of diabetes is complex and unclear. Accumulated evidence has implicated genetics, infection, immune disorders, obesity, and diet are closely related to diabetes. Diet control, reasonable exercise, oral antidiabetic drugs, and insulin injection are routine options for the prevention and treatment of diabetes. However, none of them can fundamentally prevent the development of diabetes and associated complications. During the last decade, the role of gut microbiome has drawn much attention across the world. Understanding the interplay of gut microbiome and diabetes would provide new insight into developing therapeutics for diabetes.

With the development of high-throughput sequence, research on gut microbiota breaks through the shackles of the traditional manner of living bacterium cultivation. The whole picture of gut microbiota is gradually revealed. Gut microbiota consists of more than 1000 bacterial species, mainly distributing in 9 phyla, most of which belong to the Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria [2].
The main physiological functions of gut microbiota include the following: food digestion and absorption, enhanced host immune, biological antagonism, strengthened antimicrobial responses, and synthesized beneficial compounds [3, 4]. Once the gut microbiota is out of balance, a series of diseases would be induced, including metabolic diseases, cardiovascular and cerebrovascular diseases, autoimmune diseases, inflammatory bowel disease, psychotic disorders, and cancer [5].

A number of studies have demonstrated that gut microbiota plays an important role in T2DM. Gut microbiota participates in regulating glucose and insulin sensitivity. Symptoms of diabetic patients can be improved by modifying gut microbiota, which helps to reverse the impaired glucose tolerance and fasting glucose in prediabetes. This review will focus on elucidating the correlation between gut microbiota and T2DM, the pathogenesis of T2DM mediated by gut microbiota, and the therapeutic interventions based on gut microbiota.

2. Gut Microbiota of T2DM

The first study on gut microbiota of T2DM was reported in 2010 [6]. It has been found that the abundance of class Clostridia and phylum Firmicutes in T2DM patients considerably declined, while the level of class Betaproteobacteria was highly increased and positively associated with plasma glucose. Additionally, the ratios of Bacteroidetes to Firmicutes and Bacteroides-Prevotella to C. coccoides-E. rectale are positive correlation with plasma glucose, suggesting that T2DM is correlated with the intestinal microbiota composition. In 2012, a metagenome-wide association study (MGWAS) has revealed the characterization of gut microbiota in T2DM [7]. Herein, moderate gut microbial dysbiosis is applied to characterize the gut microbiota of T2DM patients. The abundance of butyrate-producing bacteria (Clostridiales sp. SS3/4, Faecalibacterium prausnitzii, Roseburia intestinalis, Eubacterium rectale, and Roseburia inulinivorans) is decreased, while the abundance of opportunistic pathogen bacteria (Bacteroides cacaoe, Clostridium haemehwayi, Clostridium symbiosum, Eggerthella, lenta Clostridium ramosum, and Escherichia coli), mucin-degrading bacteria (Akkermanis muciniphila), and sulfate-reducing bacteria (Desulfovibrio sp. 3_1_syn3) is increased. A gut-microbiota-based T2DM classifier system can accurately classify T2D individuals, and the area under the receiver operating characteristic (ROC) curve is 0.81. Functional analysis has shown that glucose membrane transport, methane metabolism, heterogeneous biomass degradation, branched-chain amino acid transport and metabolism, and sulfate reduction pathways are enriched in patients with T2DM. Some functional genes related to flagella assembly, bacterial chemotaxis, butyrate biosynthesis, cofactors, and vitamin metabolism are decreased, while the activity of several antioxidative stress-related enzymes is upregulated in T2DM [7]. A previous study has suggested that four intestinal Lactobacillus species increased in patients with diabetes, while the abundance of five Clostridium species decreased [8]. Lactobacillus is positively correlated with fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c), while Clostridium is negatively associated with HbA1c, FBG, C peptide, insulin, and plasma triglyceride and positively correlated with high-density lipoprotein (HDL) and adiponectin [8]. The metagenomic-cluster-based T2DM identification model showed superior discriminatory power (AUC = 0.83), in which Roseburia and Faecalibacterium prausnitzii displayed highly discriminant for T2DM. Regarding the gut barrier function, signaling pathways regarding energy metabolism and absorption, glycerides, and fatty acid synthesis, cysteine and methionine metabolism are also activated [8]. Taken together, different cohort studies have shown inconsistent findings. It has also been found that the differences were mainly associated with metformin treatment, rather than diabetes itself. Excluding the biological interference of metformin, the reduction of Roseburia spp., Subdoligranulum spp., and Clostridiales spp. was significantly correlated with T2DM, and the trend of enriched Lactobacillus was reversed [9]. In addition, metformin treatment leads to higher abundance of Escheria and lower abundance of Intestinibacter, which can be explained by the adverse gastrointestinal reactions such as diarrhea, nausea, vomiting, and abdominal distension [9]. Further analysis based on gut microbial function showed that metformin treatment reduced the intestinal lipid absorption and LPS-induced inflammatory response and increased the production of butyrate and propionate [9]. In addition, many studies have further confirmed the importance of metformin in regulating gut microbiota [10, 11]. It is suggested that the study of the correlation between gut microbiota and diabetes has been proved as an alarm for the impact of antidiabetic agents on gut microbiota homeostasis with T2DM; therefore, any treatment on gut microbiota should be carefully applied.

During the past few years, researchers have investigated the role of gut microbiota in prediabetes patients or newly diagnosed without antidiabetic drugs, hoping to better explain the correlation between diabetes and gut microbiota. Allin et al. have found that the level of Clostridium and Akkermania muciniphila decreased significantly, while the level of Dorea, Ruminococcus, Sutterella, and Streptococcus increased, implicating that abnormal changes in gut microbiota occurred in the period of prediabetes [12]. Another study performed in the Swedish population has demonstrated that compared with the normal glucose tolerance (NGT) group, the composition of intestinal flora in impaired glucose tolerance (IGT), impaired fasting glucose and glucose tolerance (CGT), and untreated diabetes (T2D) groups has significantly changed, but no significant change was observed in the impaired fasting glucose (IFG) group [13]. It could be concluded that gut microbiota plays an important role in leading to diabetes by regulating systemic insulin resistance. Besides, in cases of prediabetes and T2D patients, the abundance of several butyrate producers decreased, such as Pseudoflavonifractor spp., Clostridium spp., Alstipes spp., Faecalibacterium spp., and Oscillibacter spp. The AUC of this gut-microbiota-based T2DM classifier model was 0.7. Therefore, its prediction power in distinguishing individuals with T2DM from those with NGT was moderate. However, an improved model for distinguishing T2DM and CGI had better AUC (AUC = 0.78), implicating the gut-microbiota-based classifier system could accurately assess the blood glucose status. Moreover, the ability of certain gut microbiota producing butyrate was inhibited, while genes involved in the biosynthetic pathway of intestinal biotin were

Mediators of Inflammation
significantly upregulated [13]. Accordingly, gut microbial dysbiosis plays a critical role in the pathogenesis of diabetes, which can change IGT rather than IFG.

In summary, the gut microbiota has been considered as a marker of metabolic diseases including T2DM [14]. Butyrate, metabolites of intestinal bacteria, can affect the insulin sensitivity. A decrease of butyrate has been proved to be positively correlated with diabetes [15]. Therefore, increasing the abundance of butyrate-producing bacteria or improving the butyrate synthesis ability of intestinal bacteria may be an effective method to prevent or treat diabetes.

3. Causality between Gut Microbiota and T2DM

Gut microbiota studies in large cohorts have emphasized the complex association between intestinal flora and T2DM. Animal studies from sterile mice have determined that gut microbiota is the vital cause of disease [16]. The sterile mice have lower insulin resistance and lower level of body fat than conventional mice. Subsequent gut microbiota transplantation tests have also confirmed that obesity and insulin resistance are significantly increased in sterile mice treated with ob/ob mice gut microbiota [17]. However, the results presented in sterile mice could not be used as a direct proof for human research due to the different genetic backgrounds [18]. A human study from 952 volunteers in the Netherlands finally knocked down the real hammer for the causal relationship between gut microbiota and T2DM [15]. Researchers have analyzed the whole genome and intestinal metagenome of subjects, measured fecal short-chain fatty acid (SCFA) levels, and counted clinical parameters. The causality between microbial characteristics and blood glucose characteristics was evaluated by bidirectional Mendelian Randomization (MR) analyses. It has been found that the increase of butyrate driven by host genetics was related to the improvement of insulin response after the oral glucose tolerance test. The abundance of *Eubacterium* and *Roseburia intestinalis* increased, and the abnormal level of production or absorption of propionate was related to the increased risk of T2DM. Accordingly, butyrate can promote postprandial insulin secretion and propionate generation in feces, which elevates the risk of T2DM. Nevertheless, more prospective cohort studies are warranted in different regions for deep exploration.

4. The Function of Gut Microbiota in T2DM Pathophysiology

Metabolites and components of gut microbiota affect the progress of various diseases primarily through distinct signaling pathways (Figure 1). It has been well documented that SCFAs, bile acid, branched-chain amino acids (BCAAs), imidazole propionate, and lipopolysaccharide (LPS) are important regulators in T2DM. We have discussed the detailed mechanism as follows.

4.1. SCFAs. SCFA is a metabolite produced by intestinal bacteria to metabolize dietary fiber, including acetate, propionate, and butyrate [19]. As one of the most extensively studied metabolites, SCFAs affect glucose metabolism and insulin sensitivity by participating in a variety of pathways, thereby affecting the development of diabetes. Their core functions can be summarized as follows: (1) Stimulating the secretion of intestinal hormones: SCFAs can be used as energy-regulated signaling molecules, directly bound to the free fatty acid receptor (FFAR2 or FFAR3) on the surface of intestinal L cells, and stimulate the secretion of peptide YY (YY) and glucagon-like peptide-1 (GLP-1) by colon L cells. These two intestinal hormones are responsible for delaying gastric emptying, inhibiting appetite, promoting insulin secretion, and reducing glucagon [20–23]. (2) Energy supply: SCFAs account for 5%-10% of total energy consumption in normal colon, especially butyrate [24]. (3) Increasing the intestinal gluconeogenesis: by acting in a cAMP-dependent mechanism, butyrate is able to promote the expression of intestinal gluconeogenesis-related genes. Besides, propionate is an important substrate of gluconeogenesis, which activates the intestinal gluconeogenesis-related genes through the intestinal-brain nerve circuit including FFAR3 regulating blood glucose and lipid metabolism [25]. (4) Maintaining the integrity of the intestinal barrier: the intestinal barrier in T2DM patients is damaged by proinflammatory components, including LPS resulting in insulin resistance [26, 27]. Butyrate enhances the integrity of intestinal barrier by increasing the expression of Claudin-1 mediated by the interaction between transcription factor SP1 and specific modification in the promoter region of binding protein Claudin-1, which leads to the redistribution of ZO-1 and Occludin on cell membrane [28]. Gut microbiota has been proved to operate host-secreted mucus glycoproteins as a source of nutrients under dietary fiber deficiency, and it can cause the degradation of colonic mucus barrier [29]. The addition of butyrate and propionate to human goblet-like LS174T cells can increase the expression of MUC2 mediated by acetylation/methylation of AP-1 and MUC2 promoter histones. MUC2 synthesis increases intestinal mucus thickness, ultimately leading to a decrease of intestinal permeability and protection of the integrity of intestinal barrier [30]. Moreover, acetate has been implicated as a good regulator in reducing mucosal permeability and enhancing intestinal barrier [31]. (5) Maintenance of intestinal anaerobic environment: butyrate activates peroxisome proliferator-activated receptor g (PPAR-g) in colon cells and drives the energy metabolism of colon cells to transform to β-oxidation. In addition, butyrate reduces the bioavailability of respiratory electron receptors of *Enterobacteriaceae* in the colon cavity and prevents the abnormal proliferation of opportunistic pathogenic bacteria, *Ca. Escherichia coli* and *Salmonella*, and maintains the intestinal microecological balance in T2DM patients [32]. (6) Enhanced immunity: patients with T2DM are associated with chronic low-grade inflammation [33, 34]. Symptoms of patients can be alleviated by inhibiting inflammation. Propionate can change the hematopoietic function of bone marrow in mice and increase the production of macrophages and dendritic cells [35]. Butyrate has an anti-inflammatory effect by promoting the production of regulatory T cells (Treg) and reducing inflammation [36–39].

4.2. Bile Acid. The primary bile acids are synthesized from cholesterol in the liver. Primary bile acids are secreted into
the intestine and often converted into secondary bile acids by gut microbiota, affecting glucose metabolism and insulin sensitivity through different signaling pathways [40]. Secondary bile acid stimulates the farnesoid X receptor (FXR) and leads to the release of fibroblast growth factor 19/15 (FGF19/15). FGF19/15 acts as ligands to improve insulin sensitivity and glucose tolerance. Secondary bile acid can also activate the thiol guanosine receptor-5 (TGR-5) receptor, promote muscle energy consumption and the secretion of GLP-1 by intestinal L cells, and rescue insulin resistance and abnormal glucose metabolism [41, 42]. Gut microbiota can transform primary bile acids into secondary bile acids, regulate bile acid diversity, and decouple them through bile salt hydrolase, which is essential in bile acid synthesis, modification, and signal transduction. Abnormal bile acid metabolism mediated by gut microbiota will affect the role of bile acid in the regulation of glucose metabolism [43, 44]. Recent studies have shown that the metabolism of bile acid is abnormal in patients with gut microbial dysbiosis with increased secretion of secondary bile acids such as lithocholic acid and deoxycholic acid. Bile acid stimulates the release of 5-hydroxy tryptamine by enterochromaffin cells, resulting in reduced insulin release and enhanced glucagon secretion [45]. Furthermore, bile acid can also directly cause altered structure, function, and stability of intestinal flora [46].

4.4. BCAAs. BCAAs mainly include leucine, isoleucine, and valine, which are essential amino acids for the human body. They cannot be synthesized by the host, must be obtained from diet, and are mainly produced by gut microbiota metabolism [53]. Elevated plasma level of BCAAs is a risk factor for T2DM [54–56]. Increased intake of BCAAs in diet promotes the development of T2DM and insulin resistance [57, 58]. The metagenome of gut microbiota in 277 nondiabetic and 75 diabetic patients has suggested that the functional genes of BCAA synthase and internal transport proteins were enriched in T2DM patients [59]. The main driving bacteria for the synthesis of BCAAs are *Prevotella copri* and *Bacteroides vulgatus*. Feces microbiota transplantation of *P. copri* in a mouse model can cause the insulin resistance, decrease glucose tolerance, and increase plasma BCAAs. The mechanism of insulin resistance induced by BCAA is found to be closely related to the mTOR signaling pathway. High expression of phosphorylated mTORSer2448, phosphorylated S6K1 Thr389, and phosphorylated IRS1Ser302 has been found in mice fed with BCAAs, which can block the normal conduction of insulin signaling and cause insulin resistance [60]. In addition, BCAAs can increase the oxidation of free fatty acids and activate phosphorylated 3 kinase (PI3K). PI3K activation can further induce insulin resistance through AKT phosphorylation [61]. However, further research is needed in that the exact molecular mechanism remains unclear.
4.5. *Imidazole Propionate*. The study by Koh et al. has elaborated the new mechanism that imidazole propionate, a product of histidine metabolism in the intestinal flora, affected glucose metabolism through the mTORC1 signaling pathway [62]. It has been clarified that imidazole propionate directly exerts effects on p38y mitogen-activated protein kinase (MAPK), promotes p62 protein phosphorylation, and then induces mTORC1S2448 phosphorylation. The downstream S6K1 protein phosphorylation is further activated, which causes abnormal serine phosphorylation of insulin receptor substrate, IRS degradation, and insulin resistance. A recent multicenter cohort study has revealed that imidazole propionate increased in prediabetes and T2DM patients with Bacteroides 2 enterotype and low abundance of microbial genes. It is nate increased in prediabetes and T2DM patients with Bacteroides 2 enterotype and low abundance of microbial genes. It is positively associated with the richness of Clostridium baumannii, Clostridium paraputrificum, and Ruminococcus gravis and negatively associated with anti-inflammatory bacteria [63]. Imidazole propionate was also positively correlated with systemic inflammation [63].

5. Therapies for T2DM Based on Gut Microbiota

In view of the important role of gut microbiota in T2DM pathophysiology, the prevention and treatment of diabetes by regulating intestinal flora is currently a research hotspot. Many studies have found that the characteristics of individual intestinal flora can affect the effect of traditional treatment.

5.1. Fecal Microbiota Transplantation. Fecal microbiota transplantation (FMT) is a useful treatment strategy for gastrointestinal diseases with ineffective antibiotic treatment, including ulcerative colitis, Clostridium difficile infection, and irritable bowel syndrome [64]. It is very effective in the treatment of C. difficile infection [65], and 60% of patients were cured within 1 month without serious adverse consequences [66]. In 2012, the first clinical trial of FMT in the treatment of metabolic syndrome was reported, in which nine patients with metabolic syndrome received fecal microbiota from healthy lean donors [66]. After six weeks of treatment, the insulin sensitivity was significantly improved, and the butyrate-producing bacteria increased [67]. Another larger study has demonstrated the beneficial effect of FMT in the treatment of metabolic syndrome [68]. The fecal microbiota transplantation from healthy donors to patients can effectively improve peripheral insulin resistance in the short term (6 weeks), with a decrease in HbA1c and an increase of plasma γ-aminobutyric acid (GABA) level. However, there was individual difference in patients’ response to FMT. Patients with low baseline intestinal flora diversity showed a more significant effect, suggesting that the characteristics of patients’ gut microbiota were crucial factors affecting the treatment. de Groot et al. have further demonstrated the effect of homologous FMT donors’ own metabolic characteristics on FMT by using gastric bypass donor (RYGB-D) and metabolic syndrome donor (METS-D) [69]. The results showed that the insulin sensitivity of patients with metabolic syndrome after 2 weeks of transplantation of METS-D intestinal flora was significantly reduced, accompanied by the increase of lithocholic acid, deoxycholic acid, and isolithocholic acid. However, the intestinal transit time of patients receiving RYGB-D intestinal flora was reduced, and the expression and plasma level of chemokine ligand 2 (CCL2) were increased, implicating that the donor should be carefully selected in the treatment of FMT.

5.2. Dietary Fiber. Change of food structure is the most basic auxiliary means for the treatment of diabetes, among which dietary fiber has attracted much attention due to its strong effect on improving T2DM [70, 71]. According to the Chinese Diabetes Dietary Guidelines 2019, T2DM patients should increase dietary fiber intake by 25–30 g/d, and whole grains and legume carbohydrates should account for 1/3 of the staple food. A large-scale long-term study from three forthcoming cohorts has found that the increasing amount of total whole-grain intake and commonly consumed whole-grain foods results in a decreased risk of type 2 diabetes, providing strong support for daily food recommendations of sufficient whole-grain consumption as a health-giving diet style to prevent type 2 diabetes [72]. Ma-pi diet is rich in complex carbohydrates, beans, fermented products, sea salt, and green tea, which can increase the diversity of gut microbiota, enrich short-chain fatty acid-producing bacteria and mucus-producing bacteria, such as Faecalibacterium, Akkermansia, Lachnospira, Bacteroides, and Roseburia, inhibit Collinsella and Streptococcus bacteria with proinflammatory effect, and reduce inflammation in T2DM [73, 74]. WTP diet is a high dietary fiber diet based on whole grain, supplemented by traditional Chinese medicine homologous food and probiotics [75]. The dietary fiber can enrich SCFA-producing bacteria, improve the level of intestinal SCFAs, prevent the growth of harmful bacteria, activate intestinal cells to secrete GLP-1, and increase insulin and HbA1c levels in patients. The abundance of SCFA-producing bacteria is higher with reduced HbA1c. It is worth noting that gut microbiota will also affect the response of individuals to dietary fiber. The analysis of gut microbiota between individuals with well or poor glucose metabolism after eating barley bread has revealed that *Prevotella* exists in most individuals who respond to barley bread compared with those without response to dietary intervention [76]. *Prevotella* is considered to be directly related to the effect of high fiber intake.

5.3. Probiotics. Probiotics, generally gram-positive bacteria, are defined as live microorganisms which confer health benefits on human health at an adequate level. According to current research, there are mainly three types of probiotics for diabetes: (1) common probiotics. These types of bacteria mainly from *Lactobacillus* and *Bifidobacterium* are widely used in food fermentation and have high safety in use [77, 78]. The intervention of probiotics in T2DM patients has been carried out in many clinical trials, but the results are inconsistent. Meta-analysis of multiple clinical trials showed that probiotics could effectively reduce FBG, fasting insulin, and HbA1c and improve the efficacy of HOMA-IR [79]. Another meta-analysis found that probiotics effectively reduced oxidative stress markers (TAS, TAS and MDA), and the benefits in reducing HbA1c were not clear, suggesting that probiotics mainly alleviated diabetes by improving oxidative stress rather
than glucose metabolism [80]. Sun et al. meta-analysis showed that multistrains combined with probiotic capsules were able to effectively reduce FBG and HbA1c in patients with T2DM, but the effect was not significant in patients with other risk factors [81]. The inconsistent results might be attributed to the use of strains, doses, intervention time, and single or multiple strains; thus, more clinical trials are needed to evaluate the role of conventional probiotics in preventing and improving T2DM [82]. (2) Novel probiotics. *A. muciniphila* has recently become the new candidate for probiotics to improve a variety of diseases [83–85]. The abundance of *A. muciniphila* in T2DM patients is significantly reduced [86]. Oral administration of *A. muciniphila* in mice can improve the secretion of GLP-1 in mouse colon cells [87], improve glucose tolerance [88], restore intestinal barrier, and reduce inflammation [89]. In addition, the application of *A. muciniphila* pasteurization agent and specific membrane proteins isolated from *A. muciniphila* in obese mice with diabetes significantly reduces the fat content in mice and improves insulin resistance and dyslipidemia [90]. Depommier et al. have reported *A. muciniphila* in obese patients with insulin resistance [91]. Supplementation of pasteurized *A. muciniphila* significantly improved insulin resistance and lipid metabolism but reduced liver damage and inflammation-related plasma markers. Another potential probiotic for T2DM is *Faecalibacterium prausnitzii*, an important butyrate-producing bacterium, which is negatively correlated with T2DM [13]. In db/db mice, its anti-inflammatory metabolite AMA restores the structure and function of the intestinal barrier by regulating the tight junction pathway and the expression of ZO-1 [92]. In addition, *F. prausnitzii* was significantly enriched in the treatment of diabetes through diet, fecal transplantation, drugs, and other measures (described below), which suggested that *F. prausnitzii* was very important in the treatment of T2DM. However, the application safety of this bacterium is still not clear due to a lack of effective human research. (3) Genetic engineering bacteria. The strain was genetically modified to produce biological factors for the disease. One example related to T2DM is the application of *Lactococcus lactis* as a carrier to produce GLP-1 [93]. Oral administration of the *Lactococcus lactis* can reduce blood glucose and increase insulin concentrations in rats. Nevertheless, there is still a long way to go for clinical applications of probiotics in T2DM in the future.

5.4. Exercise. Exercise is essential for improving insulin sensitivity, reducing blood glucose, and inhibiting inflammation [94, 95]. According to the *Guideline for prevention and treatment of type 2 diabetes in China*, adult patients with T2DM walk fast at least 150 min per week, play Taijiquan, cycling, table tennis, and golf, and exercise muscle strength and endurance by resistance exercise 2–3 times per week. The study of gut microbiota provides a new perspective to the mechanism by which exercise regulating diabetes. Exercise not only increases the diversity of gut microbiota but also increases the abundance of *A. muciniphila* in athletes’ intestinal flora, which is negatively correlated with obesity and T2DM [96]. Accumulated studies have shown that the abundance of *Bacteroides* increased after exercise training, while the abundance of *Clostridium genus* and *Blautia* decreased [97]. The change of gut microbiota has positive correlation with the absorption of glucose, implicating that exercise decreased the blood glucose level of diabetic patients through gut microbiota. Gut microbiota can regulate diabetes through the SCFA/FFAR/GLP-1 signaling pathway [98]. The antidiabetic efficacy of exercise is also affected by individual gut microbiota. Studies on drug-naïve and overweight diabetic patients showed that the glucose homeostasis and insulin sensitivity regulated by exercise have significant relationship to the feature of gut microbiota and the ability to metabolize and ferment proteins and carbohydrates [99]. The gut microbiota of the responders who benefit from exercise has enhanced the ability to synthesize SCFAs, GABA, and decompose BCAAs, while the gut microbiota of the nonresponders has produced more harmful metabolites. The fecal microbiota transplantation in mice has confirmed that gut microbiota improved insulin resistance by exercise. The baseline gut microbiota characteristics of patients, such as the abundance of *Bacteroides* and concentration of GABA, can accurately predict the response to exercise intervention.

6. Gut Microbiota and Antidiabetic Drugs

6.1. Metformin. Since the inception of metformin in the mid-20th century, it has become the first choice for the treatment of T2DM, which can inhibit liver gluconeogenesis and improve insulin sensitivity. However, the specific mechanism of action of metformin is still under exploration. Numbers of studies have shown that the hypoglycemic mechanism of metformin may be mediated by gut microbiota. To the best of our knowledge, metformin affects glucose metabolism targeting gut microbiota in the following aspects: (1) Balancing the ecology of intestinal microorganism, improving the disorder of gut microbiota in T2DM patients, and making it closer to healthy individuals [9]. (2) Improving the synthesis ability of SCFAs, increasing the abundance of SCFA-producing bacteria, such as *Shewanella*, *Lactobacillus*, *Blautia Bifidobacterium*, *Akkermansia*, *Prevotella*, *Megaspheara*, and *Butyrivibrio* species [9, 11, 100]. As mentioned above, SCFAs can improve insulin sensitivity and exert a hypoglycemic effect by increasing the secretion of GLP-1 and PYY. Studies have shown that metformin can indeed improve the plasma and intestinal GLP-1 levels in T2DM patients [101–103]. (3) Regulating the glucose metabolism through the bile acid pathway. Sun et al. elaborated that metformin played a hypoglycemic effect through intestinal *Bacteroides fragilis*-bile acid GUDCA-intestinal FXR metabolic axis [10]. Metformin inhibited the growth of *B. fragilis* by modifying the metabolism of folic acid and methionine, thereby reducing the activity of bile acid hydrolyse BSH and increasing the level of GUDCA. As an endogenous competitive antagonist of intestinal FXR receptor, GUDCA inhibited the FXR signaling pathway. Inhibition of the intestinal FXR signaling pathway could increase the secretion of GPL-1 and regulate glucose metabolism [104]. (4) Increasing the abundance of probiotics. In the study of gut microbiota, the increase in the abundance of probiotics (such as *Lactobacillus* and *Bifidobacterium*) after metformin administration is common [8, 10, 100]. A recent study on mice showed that SGLT1 activated in the
proximal intestine of mice through glucose induction could reduce glucose production. A high-fat diet reduced the expression of SGLT1 in the proximal ileum of mice and reduced the abundance of *Lactobacillus*. Metformin offsets these microbial changes and restores glucose sensing [105], but whether this phenomenon exists in humans needs further study. (5) Effected by imidazole propionate. As described above, imidazole propionate blocks insulin conduction through the mTORC1 signaling pathway and then induces diabetes. Recent studies showed that imidazole propionate opens the hypoglycemic effect of metformin [106]. In T2DM patients who take metformin but still have high blood glucose, the concentration of imidazole propionate is higher. The mouse experiment confirmed that imidazole propionate destroyed the hypoglycemic effect of metformin. Further cytological experiments revealed that imidazole propionate inhibited metformin-induced adenine 5'-monophosphate-activated protein kinase (AMPK) activation by inhibiting AMPK phosphorylation through the p38/ Akt pathway. The p38y inhibitory kinase could effectively block the hypoglycemic effect of imidazole propionate on metformin, which provided a new idea for the individualized treatment of diabetic patients. In addition, up to a third of patients who take metformin were reported to have gastrointestinal side effects, such as diarrhea, abdominal distension, and nausea. It has been demonstrated that metformin significantly increased the abundance of *Escherichia coli* and upregulated the corresponding virulence factors and gut metabolism genes [9, 11].

6.2. Acarbose. Acarbose is an α-glucosidase inhibitor, which reduces the digestion and absorption of carbohydrates in the small intestine, thereby reducing the postprandial blood glucose level. Acarbose completely acts in the intestine, which may partially affect the composition of distal gut microbiota. A previous study has shown that the gut microbiota of prediabetes who took acarbose changed significantly, where the abundance of *Lactobacillus*, *Faecalibacterium*, and *Dialister* was enriched [107]. Among them, *Dialister* was negatively correlated with HbA1c in prediabetes patients, indicating its potential role in glucose metabolism regulation [107]. Acarbose can also increase the abundance of *Bifidobacterium longum* and *Enterococcus faecalis* in patients with T2DM. *E. faecalis* were negatively correlated with LPS concentration, while *B. longum* was positively correlated with HDL cholesterol concentration [108]. The data from newly diagnosed T2DM patients showed that acarbose increased the abundance of *Lactobacillus* and *Bifidobacterium*, while the content of *Bacteroides* was significantly reduced. The metabolic spectrum of bile acid in plasma and feces has changed, suggesting that acarbose may affect the gut-mediated bile acid signal pathway and improve the glucose metabolism [109]. In addition, similar to metformin, the baseline characteristics of individual gut microbiota determine the therapeutic effect of acarbose. The metabolic parameters of patients with intestinal flora dominated by *Bacteroides*, including FBG, insulin, C-peptide levels, and insulin resistance, are improved more significantly compared with patients with intestinal flora dominated by *Prevotella* [109]. Accordingly, stratification of T2DM patients according to gut microbiota characteristics before treatment is useful for individualized treatment.

### Table 1: Baseline gut microbiota or bacterial metabolite characteristics of responders and nonresponders.

| Treatment      | Responders | Nonresponders | Predictors       |
|----------------|------------|---------------|-----------------|
|                | Increase   | Decrease      | Increase        | Decrease |
| **Exercise**   | Lachnospiraceae bacterium | Bacteroides xylanisolvens | Alistipes shahii | Detrimental metabolites |
| SCFAs          | GABA       | B. longum     | Alistipes putredinis | Ruminococcus graminus |
| **FMT**        | Subdoligranulum variabile | Eubacterium ventriosum | Ruminococcus torques | Low baseline diversity Subdoligranulum variabile |
| Barley bread   | Prevotella species | Bacteroides species | Prevotella copri |
| Drugs          | Metformin  | Acarbose      |                |
| Bacteroides    | Imidazole propionate | Bacteroides UDCA LCA and DCA 12-α OH/non-12α OH BA ratio | Bacteroides/Prevotella |
| UDCA           | PBA/SBA ratio | Prevotella |                |

SCFAs: short-chain fatty acids; GABA: γ-aminobutyric acid; BCAAs: branched-chain amino acids; FMT: fecal microbiota transplantation; UDCA: ursodeoxycholic acid; PBA: primary bile acids; SBA: secondary bile acids; LCA: lithocholic acid; DCA: deoxycholic acid; BA: bile acid.

6.3. Traditional Chinese Medicine. Traditional Chinese medicine has shown some advantages in improving the life quality of T2DM patients by influencing insulin resistance [110, 111]. Therefore, the *Guideline for prevention and treatment of type 2 diabetes in China* takes traditional Chinese medicine as an adjuvant drug for T2DM treatment. Many components of traditional Chinese medicine do not enter the blood, but it has a clear effect. Increasing data has suggested that its efficacy may be mediated by gut microbiota [112]. Gegenqinlian...
decoction can significantly enrich the abundance of *F. prausnitzii* in the intestinal tract of T2DM patients, which has significantly negative correlation with FBG, HbA1c, and postprandial 2h blood glucose levels and has positive correlation with HOMA-β [113], AMC, an herbal formula containing eight traditional Chinese medicines, can effectively alleviate hyperglycemia and hyperlipidemia in diabetic patients and alter the gut microbiota of T2DM patients [114]. They significantly increase the symbiotic bacteria utilized by *Blautia* spp., which is associated with lipid homeostasis and glucose. AMC shows superior effects in improving insulin resistance (HOMA-IR) and plasma triglycerides and plays a vital role in regulating gut microbiota, and only AMC increases the symbiotic bacteria using *Faecalibacterium* spp. It has been shown that berberine can effectively reduce the HbA1c of patients, and the effect of berberine in inhibiting the biotransformation of dicarboxylic acid is mediated by *Ruminococcus bromii* in T2DM [115].

7. Conclusion

Gut microbiota plays an important role in T2DM by exerting effects both in composition and function. A decrease of butyrate-producing bacteria, such as *Faecalibacterium* and *Roseburia*, and reduction of butyrate are common in T2DM, which may be the principal causes of T2DM. Several factors associated with gut microbiota have been elucidated in T2DM, including SCFAs, bile acids, LPS, BCAAs, and imidazole propionate. Gut microbiota can not only be used as a diagnostic biomarker but a potential therapeutic target for T2DM. Nevertheless, characteristics of individual gut microbiota have an important influence on different treatments, particularly the ratio of *Prevotella/Bacteroides*. As a result, the treated subjects can be divided into responders and nonresponders (Table 1). However, the exact core driving bacteria or flora is still unclear. Therefore, multicenter and comprehensive studies are warranted for further investigation. Additionally, the multiomics has been extensively applied for gut microbiota research, such as metagenomics, transcriptomics, proteomics, and metabolomics exploring the role of gut microbiota in T2DM. Elucidation of the precise role and mechanism of gut microbiota in T2DM will provide novel insight into developing individualized therapy for T2DM patients.

Data Availability

No data were used to support this study.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

We acknowledge funds from Shandong Natural Science Foundation (ZR2020KC001), Shandong Science and Technology Development Program (2016WS0657), and the Science and Technology Development Program (2016WS0657), and the Science and Technology Development Program (2016WS0657). We thank very much Professor Lili Lu for her great help for revising the manuscript.

References

[1] P. Saeedi, I. Petersohn, P. Salpea et al., “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition,” Diabetes Research and Clinical Practice, vol. 157, article 107843, 2019.

[2] S. Schloissnig, M. Arumugam, S. Sunagawa et al., “Genomic variation landscape of the human gut microbiome,” Nature, vol. 493, no. 7430, pp. 45–50, 2013.

[3] S. M. Jandhyala, R. Talukdar, C. Subramanyam, H. Vuyyuru, M. Sasikala, and D. Nageshwar Reddy, “Role of the normal gut microbiota,” World Journal of Gastroenterology, vol. 21, no. 29, pp. 8787–8803, 2015.

[4] A. M. O’Hara and F. Shanahan, “The gut flora as a forgotten organ,” EMBO Reports, vol. 7, no. 7, pp. 688–693, 2006.

[5] A. M. Valdes, J. Walter, E. Segal, and T. D. Spector, “Role of the gut microbiota in nutrition and health,” BMJ, vol. 361, article k2179, 2018.

[6] N. Larsen, F. K. Vogensen, F. W. van den Berg et al., “Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults,” PLoS One, vol. 5, no. 2, article e9085, 2010.

[7] J. Qin, Y. Li, Z. Cai et al., “A metagenome-wide association study of gut microbiota in type 2 diabetes,” Nature, vol. 490, no. 7418, pp. 55–60, 2012.

[8] F. H. Karlsson, V. Tremaroli, I. Nookaew et al., “Gut metagenome in European women with normal, impaired and diabetic glucose control,” Nature, vol. 498, no. 7452, pp. 99–103, 2013.

[9] MetaHIT consortium, K. Forslund, F. Hildebrand et al., “Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota,” Nature, vol. 528, no. 7581, pp. 262–266, 2015.

[10] L. Sun, C. Xie, G. Wang et al., “Gut microbiota and intestinal FXR mediate the clinical benefits of metformin,” Nature Medicine, vol. 24, no. 12, pp. 1919–1929, 2018.

[11] H. Wu, E. Esteve, V. Tremaroli et al., “Metformin alters the gut microbiome of individuals with treatment-naïve type 2 diabetes, contributing to the therapeutic effects of the drug,” Nature Medicine, vol. 23, no. 7, pp. 850–858, 2017.

[12] the IMI-DIRECT consortium, K. H. Allin, V. Tremaroli et al., “Aberrant intestinal microbiota in individuals with prediabetes,” Diabetologia, vol. 61, no. 4, pp. 810–820, 2018.

[13] H. Wu, V. Tremaroli, C. Schmidt et al., “The Gut Microbiota in Prediabetes and Diabetes: A Population-Based Cross-Sectional Study,” Cell Metabolism, vol. 32, no. 3, pp. 379–390.e3, 2020.

[14] M. Gurung, Z. Li, H. You et al., “Role of gut microbiota in type 2 diabetes pathophysiology,” eBioMedicine, vol. 51, article 102590, 2020.

[15] S. Sanna, N. R. van Zuydam, A. Mahajan et al., “Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases,” Nature Genetics, vol. 51, no. 4, pp. 600–605, 2019.

[16] F. Backhed, H. Ding, T. Wang et al., “The gut microbiota as an environmental factor that regulates fat storage,”
Mediators of Inflammation

[47] J. Gomes, J. A. Costa, and R. Alfenás, "Metabolic endotoxemia and diabetes mellitus: a systematic review," *Metabolism-Clinical and Experimental*, vol. 68, pp. 133–144, 2017.

[48] B. Jayashree, Y. S. Bibin, D. Prabhu et al., "Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes," *Molecular and Cellular Biochemistry*, vol. 388, no. 1-2, pp. 203–210, 2014.

[49] P. J. Pussinen, A. S. Havulinna, M. Lehto, J. Sundvall, and V. Salomaa, "Endotoxemia is associated with an increased risk of incident diabetes," *Diabetes Care*, vol. 34, no. 2, pp. 392–397, 2011.

[50] S. J. Creely, P. G. McTernan, C. M. Kusminski et al., "Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes," *American Journal of Physiology. Endocrinology and Metabolism*, vol. 292, no. 3, pp. E740–E747, 2007.

[51] D. Salamon, A. Sroka-Oleksiak, P. Kapusta et al., "Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on next-generation sequencing of the 16S rRNA gene fragment," *Polish Archives of Internal Medicine-Polskie Archiwum Medycyny Wewnętrznej*, vol. 128, no. 6, pp. 336–343, 2018.

[52] L. Rodes, A. Khan, A. Paul et al., "Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model," *Journal of Microbiology and Biotechnology*, vol. 23, no. 4, pp. 518–526, 2013.

[53] C. S. Katsanos, H. Kobayashi, M. Sheffi, C. S. Katsanos, H. Kobayashi, M. Sheffi, "Protein synthesis by essential amino acids in the elderly, is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly," *American Journal of Physiology. Endocrinology and Metabolism*, vol. 291, no. 2, pp. E381–E387, 2006.

[54] P. Giesbertz and H. Daniel, "Branched-chain amino acids as biomarkers in diabetes," *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 19, no. 1, pp. 48–54, 2016.

[55] T. Chen, Y. Ni, X. Ma et al., "Branched-chain and aromatic amino acid profiles and diabetes risk in Chinese populations," *Scientific Reports*, vol. 6, no. 1, article 20594, 2016.

[56] T. J. Wang, M. G. Larson, R. S. Vasen et al., "Metabolite profiles and the risk of developing diabetes," *Nature Medicine*, vol. 17, no. 4, pp. 448–453, 2011.

[57] G. Ashghari, H. Farhadnejad, F. Teymoori, P. Mirmiran, M. Tohidii, and F. Azizi, "High dietary intake of branched-chain amino acids is associated with an increased risk of insulin resistance in adults," *Journal of Diabetes*, vol. 10, no. 5, pp. 357–364, 2018.

[58] Y. Zheng, Y. Li, L. Qi et al., "Cumulative consumption of branched-chain amino acids and incidence of type 2 diabetes," *International Journal of Epidemiology*, vol. 45, no. 5, pp. 1482–1492, 2016.

[59] H. K. Pedersen, V. Gudmundsdottir, H. B. Nielsen et al., "Human gut microbes impact host serum metabolome and insulin sensitivity," *Nature*, vol. 535, no. 7612, pp. 376–381, 2016.

[60] C. B. Newgard, J. An, J. R. Bain et al., "A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance," *Cell Metabolism*, vol. 9, no. 4, pp. 311–326, 2009.

[61] T. Kawaguchi, N. Izumi, M. R. Charlton, and M. Sata, "Branched-chain amino acids as pharmacological nutrients in chronic liver disease," *Hepatology*, vol. 54, no. 3, pp. 1063–1070, 2011.

[62] A. Koh, A. Molinaro, M. Stählin et al., "Microbiologically produced imidazole propionate impairs insulin signaling through mTORC1," *Cell*, vol. 175, no. 4, pp. 947–961.e17, 2018.

[63] The MetaCardis Consortium, A. Molinaro, P. Bel Lassen et al., "Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology," *Nature Communications*, vol. 11, no. 1, article 5881, 2020.

[64] H. Antushevich, "Fecal microbiota transplantation in disease therapy," *Clínica Chirica Acta*, vol. 503, pp. 98–90, 2020.

[65] E. Gough, H. Shaikh, and A. R. Manges, "Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection," *Clinical Infections Diseases*, vol. 53, no. 10, pp. 994–1002, 2011.

[66] B. Cui, Q. Feng, H. Wang et al., "Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results," *Journal of Gastroenterology and Hepatology*, vol. 30, no. 1, pp. 51–58, 2015.

[67] A. Vrieze, E. van Nood, F. Holleman et al., "Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome," *Gastroenterology*, vol. 143, no. 4, pp. 913–916.e7, 2012.

[68] R. S. Kootte, E. Levin, J. Salojärvi et al., "Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition," *Cell Metabolism*, vol. 26, no. 4, pp. 611–619.e6, 2017.

[69] P. de Groot, T. Scheithauer, G. J. Bakker et al., "Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time," *Gut*, vol. 69, no. 3, pp. 502–512, 2020.

[70] M. P. Mcrae, "Dietary Fiber Intake and Type 2 Diabetes Melitus: An Umbrella Review of Meta-analyses," *Journal of Chiropractic Medicine*, vol. 17, no. 1, pp. 44–53, 2018.

[71] L. Velázquez-López, A. V. Muñoz-Torres, C. García-Peña, M. López-Alarcón, S. Islas-Andrade, and J. Escobedo-de la Peña, "Fiber in diet is associated with improvement of glycated hemoglobin and lipid profile in Mexican patients with type 2 diabetes," *Journal of Diabetes Research*, vol. 2016, Article ID 2980406, 9 pages, 2016.

[72] Y. Hu, M. Ding, L. Sampson et al., "Intake of whole grain foods and risk of type 2 diabetes: results from three prospective cohort studies," *BMJ*, vol. 370, p. m2206, 2020.

[73] M. Candela, E. Biagi, M. Soverini et al., "Modulation of gut microbiota dysbioses in type 2 diabetic patients by microbiotic Ma-Pi 2 diet," *The British Journal of Nutrition*, vol. 116, no. 1, pp. 80–93, 2016.

[74] F. Fallucca, C. Porrata, S. Fallucca, and M. Pianesi, "Influence of diet on gut microbiota, inflammation and type 2 diabetes mellitus. First experience with microbiotic Ma-Pi 2 diet," *Diabetes/metabolism research and reviews*, vol. 30, Supplement 1, pp. 48–54, 2014.

[75] L. Zhao, F. Zhang, X. Ding et al., "Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes," *Science*, vol. 359, no. 6380, pp. 1151–1156, 2018.

[76] P. Kovatcheva-Datchary, A. Nilsson, R. Akrami et al., "Dietary Fiber-Induced Improvement in Glucose Metabolism Is
Associated with Increased Abundance of *Prevotella*, "Cell Metabolism," vol. 22, no. 6, pp. 971–982, 2015.

[77] R. George Kerry, J. K. Patra, S. Gouda, Y. Park, H. S. Shin, and G. Das, "Benefit of probiotics for human health: a review," *Journal of Food and Drug Analysis*, vol. 26, no. 3, pp. 927–939, 2018.

[78] V. P. Singh, J. Sharma, S. Babu, Rizwanulla, and A. Singla, "Role of probiotics in health and disease: a review," *Journal of the Pakistan Medical Association*, vol. 63, no. 2, pp. 253–257, 2013.

[79] Y. W. Tao, Y. L. Gu, X. Q. Mao, L. Zhang, and Y. F. Pei, "Effects of probiotics on type II diabetes mellitus: a meta-analysis," *Journal of Translational Medicine*, vol. 18, no. 1, p. 30, 2020.

[80] E. Ardeshirlarijani, O. Tabatabaei-Malazy, S. Mohseni, M. Qorbani, B. Larjani, and R. Baradar Jalili, "Effect of probiotics supplementation on glucose and oxidative stress in type 2 diabetes mellitus: a meta-analysis of randomized trials," *DARU-Journal of Pharmaceutical Sciences*, vol. 27, no. 2, pp. 827–837, 2019.

[81] J. Sun and N. J. Buys, "Glucose- and glycemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebo-controlled trials," *The British Journal of Nutrition*, vol. 115, no. 7, pp. 1167–1177, 2016.

[82] Z. Sun, X. Sun, J. Li et al., "Using probiotics for type 2 diabetes mellitus intervention: advances, questions, and potential," *Critical Reviews in Food Science and Nutrition*, vol. 60, no. 4, pp. 670–683, 2020.

[83] D. Cheng and M. Z. Xie, "A review of a potential and promising probiotic candidate-Akkermansia muciniphila," *Journal of Applied Microbiology*, vol. 130, no. 6, pp. 1813–1822, 2021.

[84] Q. Zhai, S. Feng, N. Arjan, and W. Chen, "A next generation probiotic, Akkermansia muciniphila," *Critical Reviews in Food Science and Nutrition*, vol. 59, no. 19, pp. 3227–3236, 2019.

[85] E. Ansaldo, L. C. Slayden, K. L. Ching et al., "Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis," *Science*, vol. 364, no. 6446, pp. 1179–1184, 2019.

[86] M. C. Dao, A. Everard, J. Aron-Wisewsky et al., "Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology," *Gut*, vol. 65, no. 3, pp. 426–436, 2016.

[87] C. H. Hansen, L. Krych, D. S. Nielsen et al., "Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse," *Diabetologia*, vol. 55, no. 8, pp. 2285–2294, 2012.

[88] S. Zhao, W. Liu, J. Wang et al., "Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice," *Journal of Molecular Endocrinology*, vol. 58, no. 1, pp. 1–14, 2017.

[89] A. Everard, C. Belzer, L. Geurts et al., "Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 22, pp. 9066–9071, 2013.

[90] H. Plovier, A. Everard, C. Druart et al., "A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice," *Nature Medicine*, vol. 23, no. 1, pp. 107–113, 2017.

[91] C. Depommier, A. Everard, C. Druart et al., "Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study," *Nature Medicine*, vol. 25, no. 7, pp. 1096–1103, 2019.

[92] J. Xu, R. Liang, W. Zhang et al., "Facecalibacterium prausnitzi-i-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression," *Journal of Diabetes*, vol. 12, no. 3, pp. 224–236, 2020.

[93] P. Agarwal, P. Khatri, B. Billack, W. K. Low, and J. Shao, "Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis," *Pharmaceutical Research*, vol. 31, no. 12, pp. 3404–3414, 2014.

[94] T. Teich, D. P. Zahrarieva, and M. C. Riddell, "Advances in exercise, physical activity, and diabetes mellitus," *Diabetes Technology & Therapeutics*, vol. 21, Supplement 1, pp. S-112–S-122, 2019.

[95] D. W. Jenkins and A. Jenks, "Exercise and diabetes: a narrative review," *Journal of foot surgery*, vol. 56, no. 5, pp. 968–974, 2017.

[96] S. F. Clarke, E. F. Murphy, O. Sullivan et al., "Exercise and associated dietary extremes impact on gut microbial diversity," *Gut*, vol. 63, no. 12, pp. 1913–1920, 2014.

[97] K. K. Motiani, M. C. Collado, J. J. Eskelinen et al., "Exercise training modulates gut microbiota profile and improves endotoxemia," *Medicine and Science in Sports and Exercise*, vol. 52, no. 1, pp. 94–104, 2020.

[98] H. Hamasaki, "Exercise and glucagon-like peptide-1: does exercise potentiate the effect of treatment?", *World Journal of Diabetes*, vol. 9, no. 8, pp. 138–140, 2018.

[99] Y. Liu, Y. Wang, Y. Ni et al., "Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention," *Cell Metabolism*, vol. 31, no. 1, pp. 77–91.e5, 2020.

[100] J. de la Cuesta-Zuluaga, N. T. Mueller, V. Corrales-Agudelo et al., "Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbota in the gut," *Diabetes Care*, vol. 40, no. 1, pp. 54–62, 2017.

[101] E. Mannucci, F. Tesi, G. Bardini et al., "Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes," *Diabetes, Nutrition & Metabolism*, vol. 17, no. 6, pp. 336–342, 2004.

[102] W. C. Knowler, E. Barrett-Connor, S. E. Fowler et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin," *The New England Journal of Medicine*, vol. 346, no. 6, pp. 393–403, 2002.

[103] L. J. Mccreight, C. J. Bailey, and E. R. Pearson, "Metformin and the gastrointestinal tract," *Diabetologia*, vol. 59, no. 3, pp. 426–435, 2016.

[104] M. S. Trabelsi, M. Daoudi, J. Prawitt et al., "Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine I cells," *Nature Communications*, vol. 6, no. 1, p. 7629, 2015.

[105] P. V. Bauer, F. A. Duca, T. Waise et al., "Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-SGLT1-Sensing Glucoregulatory Pathway," *Cell Metabolism*, vol. 27, no. 1, pp. 101–117.e5, 2018.

[106] A. Koh, L. Manner-Rok-Holm, N. O. Yunn et al., "Microbial Imidazole Propionate Affects Responses to Metformin through p38y-Dependent Inhibitory AMPK Phosphorylation," *Cell Metabolism*, vol. 32, no. 4, pp. 643–653.e4, 2020.
[107] X. Zhang, Z. Fang, C. Zhang et al., “Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial,” *Diabetes Therapy*, vol. 8, no. 2, pp. 293–307, 2017.

[108] B. Su, H. Liu, J. Li et al., “Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus,” *Journal of Diabetes*, vol. 7, no. 5, pp. 729–739, 2015.

[109] Y. Gu, X. Wang, J. Li et al., “Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment,” *Nature Communications*, vol. 8, no. 1, article 1785, 2017.

[110] J. Wang, Q. Ma, Y. Li et al., "Research progress on traditional Chinese medicine syndromes of diabetes mellitus," *Biomedicine & Pharmacotherapy*, vol. 121, article 109565, 2020.

[111] J. Tian, D. Jin, Q. Bao et al., "Evidence and potential mechanisms of traditional Chinese medicine for the treatment of type 2 diabetes: a systematic review and meta-analysis," *Diabetes Obesity & Metabolism*, vol. 21, no. 8, pp. 1801–1816, 2019.

[112] Q. Nie, H. Chen, J. Hu, S. Fan, and S. Nie, "Dietary compounds and traditional Chinese medicine ameliorate type 2 diabetes by modulating gut microbiota," *Critical Reviews in Food Science and Nutrition*, vol. 59, no. 6, pp. 848–863, 2019.

[113] J. Xu, F. Lian, L. Zhao et al., "Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula," *ISME Journal*, vol. 9, no. 3, pp. 552–562, 2015.

[114] X. Tong, J. Xu, F. Lian et al., "Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized, open label clinical trial," *mBio*, vol. 9, no. 3, 2018.

[115] Y. Zhang, Y. Gu, H. Ren et al., "Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)," *Nature Communications*, vol. 11, no. 1, article 18414, p. 5015, 2020.